Episode Details
Back to EpisodesFDA Issues CRL to Regeneron for Eylea HD Extended Dosing
Published 1 year, 1 month ago
Description
The FDA responds to Regeneron’s request to extend dosing intervals for Eylea HD; Regeneron applies for a new indication for Eylea HD; and several recent executive appointments are announced in the ophthalmology industry.
Learn more about your ad choices. Visit megaphone.fm/adchoices